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Abstract
The human calcium-sensing receptor (CaSR) is a 1078-amino-acid cell surface protein which is expressed in the
parathyroids, thyroid cells and the kidney, and is a member of the family of G protein-coupled receptors. The CaSR allows
regulation of parathyroid hormone (PTH) secretion and renal tubular calcium reabsorption in response to alterations in
extracellular calcium concentrations. The human CaSR gene is located on chromosome 3q13.3^q21, and loss of function
CaSR mutations have been reported in the hypercalcaemic disorders of familial benign (hypocalciuric) hypercalcaemia (FBH
or FHH) and neonatal severe primary hyperparathyroidism (NSHPT). In addition, gain of function CaSR mutations have
been observed in a novel familial syndrome of hypocalcaemia with hypercalciuria. The human CaSR gene on chromosome
3q13.3^q21 is likely to be one of several, as two other loci for FBH have been located on chromosome 19p and 19q13.
Cloning and characterisation of these genes will help to further elucidate the mechanisms regulating extracellular
calcium. ß 1998 Elsevier Science B.V. All rights reserved.
Keywords: Hypercalcaemia; Hypocalcaemia; G-protein coupled receptor
1. Introduction
Calcium homeostasis by the kidneys and parathy-
roids is mediated by the calcium-sensing receptor
(CaSR), which is located on 3q21^q24 and belongs
to family C of the superfamily of G-protein coupled
receptors that includes those for metabotrophic glu-
tamate, certain pheromones, and Q-aminobutyric acid
(GABAB) [1,2]. Inactivating CaSR mutations result
in familial benign (hypocalciuric) hypercalcaemia
(FBH or FHH), whilst activating mutations result
in hypocalcaemic hypercalciuria [3^8].
2. Disorders due to loss of CaSR function
Two hypercalcaemic disorders due to mutations of
the CaSR have been reported [4,5,9^12]; these are
familial benign hypercalcaemia (FBH), which is
also referred to as familial hypocalciuric hypercalcae-
mia (FHH), and neonatal severe hyperparathyroid-
ism (NSHPT). FBH is an autosomal dominant dis-
order characterised by lifelong and generally
asymptomatic hypercalcaemia [13,14]. Other bio-
chemical features include mild hypermagnesaemia,
normal or mildly elevated serum PTH concentra-
tions and an inappropriately low urinary calcium
excretion (calcium clearance to creatinine clearance
ratio6 0.01) [13^16]. The disorder is considered to be
benign as patients with FBH are usually asympto-
matic. However, there is an increased prevalence of
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chondrocalcinosis with advancing age and occasional
cases of acute pancreatitis have been reported [13,15^
17]. An association of a progressive elevation in
serum PTH concentration, hypophosphataemia and
osteomalacia with FBH in a ¢ve-generation FBH
kindred from Oklahoma (FBHOk) has also been
documented [18]. In contrast, NSHPT is a life-
threatening disorder characterised by severe neo-
natal hypercalcaemia, failure to thrive, bony under-
mineralisation, multiple fractures and rib cage de-
formity [16]. NSHPT was recognised amongst some
children born to consanguineous FBH parents and
was thus considered to be the homozygous pheno-
type of FBH [19^21].
Investigations of FBH had revealed an abnormal-
ity in calcium sensing that was associated with an
altered ‘set point’ for the regulation of PTH by ionic
calcium [22,23]. Expression cloning studies, in which
RNA from bovine parathyroid glands was injected
into Xenopus oocytes, were successful in isolating a
bovine parathyroid calcium-sensing receptor (BoP-
CaR1) [24]. The BoPCaR1 gene encodes a protein
of 1085 amino acids with three structural domains
that consisted of: a large N-terminal domain of
613 amino acids containing nine potential N-linked
glycosylation sites consistent with an extracellular
location; a central core of 250 amino acids, contain-
ing seven hydrophobic helices characteristic of the G
protein-coupled receptor superfamily; and a predom-
inantly hydrophilic 222-amino-acid C-terminus pre-
dicted to be cytoplasmic. The BoPCaR1 has homol-
ogy to the brain metabotropic glutamate receptors
(mGluRs), having 29% amino acid identity to the
rat mGluR1 protein, and the bovine, human and
rat CaSRs and the mGluRs probably share a com-
mon framework of secondary structure with 20 con-
served cysteine residues [25]. The human homologue
of the BoPCaR1 gene, which shares 93% overall ami-
no acid identity with BoPCaR1 and the rat CaSR,
was mapped to chromosome 3q13^21 [4,26^29]. The
CaSR functions through the activation of phospho-
lipase C via an as yet uncharacterised, but pertussis
toxin-insensitive, G protein in the parathyroid cells
and allows the regulation of PTH secretion [24]. In-
terestingly, the rat CaSR is also expressed in the
thyroid C-cells, the renal medullary thick ascending
limb, cerebral arteries, brain nerve terminals, hypo-
thalamus and pituitary [26^28].
Mutational analyses of the human CaSR have re-
vealed di¡erent mutations, that result in a loss of
Fig. 1. Location of calcium-sensing receptor mutations found in FBH, NSHPT and hypocalcaemic hypercalciuric kindreds. A sche-
matic representation of the calcium-sensing receptor, which consists of a large extracellular domain, seven transmembrane domains
and an intracellular carboxy-terminal domain, is shown together with 36 di¡erent mutations. Each missense mutation is shown in the
single letter amino acid code: A, alanine; C, cysteine; D, aspartate; E, glutamate; F, phenylalanine; G, glycine; H, histidine; I, iso-
leucine; M, methionine; N, asparagine; P, proline; Q, glutamine; R, arginine; S, serine; T, threonine; V, valine; W, tryptophan; Y,
tyrosine. The nonsense mutation found at codon 607 is shown as S607stop.
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function of the CaSR in patients with FBH and
NSHPT [4,6,9^12] (Fig. 1). Many of these mutations
cluster around the aspartate and glutamate rich re-
gions (codons 39^300) within the extracellular do-
main of the receptor [4,6,9,11,12], and this has been
proposed to contain low-a⁄nity calcium-binding
sites, based on similarities to that of calsequestrin,
in which the ligand-binding pockets also contain neg-
atively charged amino acid residues [24]. Approxi-
mately two-thirds of the FBH kindreds investigated
have been found to have unique heterozygous muta-
tions of the CaSR [4,6,9^12]. Expression studies of
the FBH associated CaSR mutations have demon-
strated a loss of CaSR function whereby there is an
increase in the calcium ion-dependent set-point for
PTH release from the parathyroid cell [4,12]. NSHPT
occurring in the o¡spring of consanguineous FBH
families has been shown to be due to homozygous
CaSR mutations [4,9,10,30]. However, patients with
sporadic NSHPT have been reported to be associated
with de novo heterozygous CaSR mutations [6],
thereby suggesting that factors other than mutant
gene dosage [30] ; for example, the degree of set-point
abnormality, the bony sensitivity to PTH and the
maternal extracellular calcium concentration may
also all play a role in the phenotypic expression of
a CaSR mutation in the neonate. The remaining one-
third of FBH families in whom a mutation within the
coding region of the CaSR has not been demon-
strated may either have an abnormality in the pro-
moter of the gene or a mutation at one of the two
other FBH loci that have been revealed by family
linkage studies. These FBH loci are located on chro-
mosome 19p and 19q13.
3. Disorders due to gain of CaSR function
CaSR mutations that result in a loss of function
are associated with familial hypocalciuric hypercal-
caemia (FHH) [4,5,9^12], and it was speculated
that CaSR mutations that resulted in a gain of func-
tion may lead to hypocalcaemia with hypercalciuria.
Investigation of kindreds with autosomal dominant
forms of hypocalcaemia have identi¢ed such CaSR
mutations [7,31^34]. A¡ected individuals from such
families generally have normal serum intact PTH
concentrations and hypomagnesaemia. However,
treatment with vitamin D or its active metabolites
to correct the hypocalcaemia has resulted in marked
hypercalciuria, nephrocalcinosis, nephrolithiasis and
renal impairment, which was partially reversible after
cessation of the vitamin D treatment. All of the 10
CaSR mutations resulting in such a functional gain
have been missense mutations, and eight of these are
located within the extracellular domain [7,31^34]
(Fig. 1). This suggests that these mutations of the
extracellular domain may increase the a⁄nity of
the receptor for calcium binding. Thus, it is impor-
tant to identify and avoid vitamin D treatment in
such patients and families whose hypocalcaemia is
due to a CaSR abnormality and not hypoparathy-
roidism.
4. Conclusion
The identi¢cation of the extracellular calcium-sens-
ing receptor (CaSR) has helped to de¢ne a key com-
ponent in the control of the calcium homeostasis. In
addition, loss of function of the CaSR has been
shown to be associated with hypercalcaemic disor-
ders of FHH and NSHPT, whilst gain of CaSR func-
tion is associated with a novel familial syndrome of
hypocalcaemia with hypercalciuria.
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